信号转导与转录活化蛋白STAT3在肿瘤发生中的作用

STAT3是信号转导与转录活化蛋白（STAT）家族的一个重要成员,也是一个可以被多种调控细胞增殖、分化、发育、存活和炎症的细胞因子、生长因子及肿瘤蛋白所激活的关键信号转导蛋白。在多种肿瘤细胞、细胞性状转化过程和肿瘤形成过程中可以检测到组成性激活的STAT3。我们从STAT3在肿瘤细胞中组成性激活的机制、STAT3作为转录因子对肿瘤细胞调控的机制等方面对STAT3在肿瘤发生中的作用进行简要综述。     

抗肿瘤天然药物抑制STAT3 信号通路的分子机制研究进展

信号转导和转录激活因子3（STAT3）是细胞内重要的信号转导蛋白和转录因子,与肿瘤的发生发展密切相关,抑制其信号通路,可抑制肿瘤生长与转移,故近年来将STAT3 蛋白作为抗肿瘤靶点,开发STAT3 抑制剂,已成为研究热点。概述STAT3 及其信号通路与肿瘤发生、发展和转移的关系以及STAT3 信号通路的主要抑制途径,重点综述抗肿瘤天然药物抑制STAT3 信号通路的分子机制研究进展。     

Axin在肿瘤发生中的作用机制

阐明肿瘤发生机制的细胞信号转导途径的研究是当今生物医学领域研究的热点。Axin是一个肿瘤抑制因子,它以构架蛋白的形式在Wnt、JNK、p53、TGF-β、G蛋白信号转导途径等众多信号转导途径中参与细胞生长、增殖、分化、癌变和凋亡等多种重要细胞命运的调控过程。现从Axin的发现、Axin通过多种信号转导途径抑制肿瘤发生和AXIN1基因突变与肿瘤发生之间的关系这三个方面介绍肿瘤抑制因子Axin与肿瘤之间的研究进展。     

经典Wnt信号通路与人类肿瘤

近年来,随着对肿瘤的深入研究,Wnt信号的研究也受到了高度的关注．Wnt信号通路是一条在进化上保守的信号途径,在控制胚胎发育,调节细胞生长、迁移、分化,调控正常组织重建等生命活动中发挥重要的作用,其异常活化与众多人类肿瘤的发生、发展密切相关．Wnt信号途径异常的核心是β-catenin在细胞内累积,并通过其下游途径引起特异靶基因的转录．本文着重介绍Wnt/β-catenin信号转导通路的研究进展及其与肿瘤的关系,了解该通路在肿瘤发生过程中的具体分子机制有助于为临床诊断提供依据,为早期干预治疗提供方法．     

STAT3与在肿瘤耐药中的研究进展

STAT3是信号转导与转录活化蛋白(STATs)家族的重要一员,是一种存在于胞浆并在激活后能够转入核内与DNA结合的蛋白家族,具有信号转导和转录调控双重功能。STAT3在多种肿瘤组织与细胞系中异常表达,并与肿瘤的增殖分化、细胞凋亡密切相关。肿瘤耐药是其治疗失败的重要原因,STAT3能够通过多种途径介导肿瘤耐药。因而,STAT3在近年的抗肿瘤研究中备受关注,成为肿瘤治疗的良好靶点,由传统药物与STAT3抑制剂组成的新型治疗方案使得肿瘤患者大大受益。然而,STAT3介导肿瘤耐药的机制还不是很明确,需要进一步研究。本文就近年来一些化疗药物和靶向药物耐药的发生,对STAT3介导耐药的作用进行综述。     

寡糖对JAK-STAT信号转导通路的调节机制

寡糖类化合物对细胞因子的JAK-STAT信号转导途径具有免疫抑制作用.进一步研究寡糖类化合物对JAK-STAT信号转导途径的影响,对研究和开发寡糖类免疫调节药物具有重受意义.     

PI3K/Akt信号传导通路与肿瘤

信号转导通路的异常激活是肿瘤细胞的发生、发展重要步骤,PI3K/Akt 信号通路在人类绝大多数恶性肿瘤中被异常激活,其在肿瘤的增殖、存活、细胞运动、抵抗凋亡、血管发生和转移以及对化疗耐药、放疗抗拒中发挥了重要作用.因此,通过对PI3K/Akt 通路的研究进一步了解肿瘤的发生、发展机制,并寻求抗肿瘤药物的新靶点,本文就 PI3K/Akt 信号转导通路的结构特点、与肿瘤发生、发展的关系及其时放化疗的影响作一综述.     

新型抗癌药物分子靶标STAT3的研究进展

信号转导与转录激活因子(STATs)是一类发挥信号转导和转录因子调节作用的蛋白质家族,它们可以作为信号转导分子和转录调节因子参与到细胞因子和生长因子对于正常细胞的调控作用中。STATs的异常激活,特别是STAT3激活,和多种人类恶性肿瘤相关联。相关的分子生物学和药理学模型的研究也已确认STAT3在肿瘤发生中的重要作用,这些工作为抗癌药物研发和治疗癌症提供了新的靶标。此外,结构性活化的STAT3突变体就足以诱导瘤原细胞的转化,并且进一步在体内形成肿瘤。结构性激活的STAT3信号通路常常伴随着一些基因如cyclinD1,c-Myc和Bcl-x的上调,同时也会破坏正常细胞生长与生存的调控机制。体外和体内的实验研究结果也证明,对于STAT3信号通路结构性的阻断可以导致STAT3高表达肿瘤类型中的细胞生长抑制和凋亡。这种已被证实了的肿瘤细胞内的结构性激活和生长存活之间的相互联系,为癌症治疗提供了广阔的应用前景。近年来针对STAT3抑制剂的研究逐渐成为热点,本文就此作一综述。     

The JAK-STAT Transcriptional Regulator,STAT-5, Activates the ATM DNA Damage Pathway to Induce HPV 31 Genome Amplification upon Epithelial Differentiation

High-risk human papillomavirus (HPV) must evade innate immune surveillance to establish persistent infections and to amplify viral genomes upon differentiation. Members of the JAK-STAT family are important regulators of the innate immune response and HPV proteins downregulate expression of STAT-1 to allow for stable maintenance of viral episomes. STAT-5 is another member of this pathway that modulates the inflammatory response and plays an important role in controlling cell cycle progression in response to cytokines and growth factors. Our studies show that HPV E7 activates STAT-5 phosphorylation without altering total protein levels. Inhibition of STAT-5 phosphorylation by the drug pimozide abolishes viral genome amplification and late gene expression in differentiating keratinocytes. In contrast, treatment of undifferentiated cells that stably maintain episomes has no effect on viral replication. Knockdown studies show that the STAT-5β isoform is mainly responsible for this activity and that this is mediated through the ATM DNA damage response. A downstream target of STAT-5, the peroxisome proliferator-activated receptor γ (PPARγ) contributes to the effects on members of the ATM pathway. Overall, these findings identify an important new regulatory mechanism by which the innate immune regulator, STAT-5, promotes HPV viral replication through activation of the ATM DNA damage response.     

Benzyl isothiocyanate suppresses pancreatic tumor angiogenesis and invasion by inhibiting HIF-α/VEGF/Rho-GTPases: pivotal role of STAT-3

Our previous studies have shown that benzyl isothiocyanate (BITC) suppresses pancreatic tumor growth by inhibiting STAT-3; however, the exact mechanism of tumor growth suppression was not clear. Here we evaluated the effects and mechanism of BITC on pancreatic tumor angiogenesis. Our results reveal that BITC significantly inhibits neovasularization on rat aorta and Chicken-Chorioallantoic membrane. Furthermore, BITC blocks the migration and invasion of BxPC-3 and PanC-1 pancreatic cancer cells in a dose dependant manner. Moreover, secretion of VEGF and MMP-2 in normoxic and hypoxic BxPC-3 and PanC-1 cells was significantly suppressed by BITC. Both VEGF and MMP-2 play a critical role in angiogenesis and metastasis. Our results reveal that BITC significantly suppresses the phosphorylation of VEGFR-2 (Tyr-1175), and expression of HIF-α. Rho-GTPases, which are regulated by VEGF play a crucial role in pancreatic cancer progression. BITC treatment reduced the expression of RhoC whereas up-regulated the expression of tumor suppressor RhoB. STAT-3 over-expression or IL-6 treatment significantly induced HIF-1α and VEGF expression; however, BITC substantially suppressed STAT-3 as well as STAT-3-induced HIF-1α and VEGF expression. Finally, in vivo tumor growth and matrigel-plug assay show reduced tumor growth and substantial reduction of hemoglobin content in the matrigel plugs and tumors of mice treated orally with 12 μmol BITC, indicating reduced tumor angiogenesis. Immunoblotting of BITC treated tumors show reduced expression of STAT-3 phosphorylation (Tyr-705), HIF-α, VEGFR-2, VEGF, MMP-2, CD31 and RhoC. Taken together, our results suggest that BITC suppresses pancreatic tumor growth by inhibiting tumor angiogenesis through STAT-3-dependant pathway.     

Human leptin signaling in human peripheral blood mononuclear cells: activation of the JAK-STAT pathway

Leptin is an adipocyte-secreted hormone that centrally regulates weight control. However, the leptin receptor is expressed not only in the central nervous system, but also in other systems, such as reproductive, hematopoietic, and immune tissues, suggesting various roles in addition to the regulation of food intake and energy expenditure. The leptin receptor bears homology to members of the class I cytokine receptor family. Leptin has previously been shown to enhance cytokine production by murine peritoneal macrophages and human circulating monocytes, where human leptin promotes activation and proliferation. We have recently found that the leptin receptor is expressed not only in monocytes but also in both CD4(+) and CD8(+) T lymphocytes. Besides, leptin enhances proliferation and activation of T lymphocytes when they are costimulated by PHA or Con A. In this paper, we have studied the signal transduction of the leptin receptor in peripheral blood mononuclear cells. We found that leptin stimulation activates the JAK-STAT signaling pathway. More specifically, we found that JAK-2/3 and STAT-3 are activated by tyrosine phosphorylation upon leptin stimulation. Moreover, leptin stimulated tyrosine phosphorylation of the RNA binding protein Sam68 and its association with STAT-3. These effects were dose-dependent (0.1-10 nM) and transient (5-30 min). We also observed the leptin stimulated translocation of activated STAT-3 from the cytoplasm to the nucleus. These results indicate that human leptin receptor in circulating mononuclear cells has the signaling capacity to activate JAK-STAT cascade. This pathway may mediate, at least in part, the action of human leptin in human peripheral blood mononuclear cells.